SOUTH SAN FRANCISCO, Calif. – May 6, 2020 – Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel, disease-modifying therapeutic approach to treat what it believes to be a key underlying cause of Alzheimer’s (AD) and other degenerative diseases, today announced the publication of research further documenting the ability of the pathogen...
Posted Yesterday Advances in the sciences have made it easier than ever to live with and survive various kinds of cancer. One of the lingering challenges that remains is metastasis, or the ability of cancer cells to migrate to new pathological sites within the host’s body. October is National Breast Cancer Awareness Month. Too many...
Posted Today A new study has recently questioned the idea that pathological gaming – loosely defined as gaming at the expense of building and maintaining social relationships and other facets of daily life – is a discrete mental disorder caused by the distinctly addictive nature of video games themselves, and suggested a different model whereby...
A single misbehaving protein—called TDP-43—is behind 97 percent of amyotrophic lateral sclerosis (ALS) cases and 45 percent of frontotemporal dementia diagnoses. It also is found in 80 percent of chronic traumatic encephalopathy and 60 percent of Alzheimer’s disease cases. Now, University of Pittsburgh researchers have found a way to trap TDP-43 so it doesn’t form...
